Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sequential Envafolimab Immunotherapy After Patients With ctDNA EGFR Mutation Clearance by Treatment With Almonertinib in EGFR-Mutant, PD-LI Positive Non-small-cell Lung Cancer：Efficacy and Safety Clinical Trial

NCT05534113 is registered in ClinicalTrials.gov with The First Affiliated Hospital with Nanjing Medical University as lead sponsor.

NCT NCT05534113
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05534113 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sequential Envafolimab Immunotherapy After Patients With ctDNA EGFR Mutation Clearance by Treatment With Almonertinib in EGFR-Mutant, PD-LI Positive Non-small-cell Lung Cancer：Efficacy and Safety Clinical Trial
Lead sponsor
The First Affiliated Hospital with Nanjing Medical University
Phase
Phase 2
Overall status
Unknown status
Start date
December 1, 2022
Completion date
June 1, 2025
Enrollment
38 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer